Abstract
This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer. This trial was initiated to 1) determine the maximum tolerated dose and dose-limiting toxicities of UFT plus calcium folinate (Orzel) administered three times per day for 21 days in combination with paclitaxel; and 2) define the appropriate dose for phase H testing. Thus far, 14 patients have been accrued to three dose levels. Two patients developed dose-limiting toxicities at dose level 3. One patient experienced grade 3 hypotension. A second patient experienced grade 3 vomiting, grade 4 diarrhea, and severe hand-foot syndrome. Two partial responses and one complete response have been observed. Early trends suggest that this regimen is active in metastatic breast cancer and is well tolerated. Completion of this study is anticipated in 1999.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 69-70 |
| Number of pages | 2 |
| Journal | Oncology |
| Volume | 13 |
| Issue number | 7 SUPPL. |
| State | Published - 1999 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. / Dickson, Natalie R.; Nicholson, Brenda P.; Hande, Kenneth; Blanke, Charles; Johnson, David; Cohen, Alan.
In: Oncology, Vol. 13, No. 7 SUPPL., 1999, p. 69-70.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Paclitaxel, UFT, and calcium folinate in metastatic breast cancer
AU - Dickson, Natalie R.
AU - Nicholson, Brenda P.
AU - Hande, Kenneth
AU - Blanke, Charles
AU - Johnson, David
AU - Cohen, Alan
PY - 1999
Y1 - 1999
N2 - This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer. This trial was initiated to 1) determine the maximum tolerated dose and dose-limiting toxicities of UFT plus calcium folinate (Orzel) administered three times per day for 21 days in combination with paclitaxel; and 2) define the appropriate dose for phase H testing. Thus far, 14 patients have been accrued to three dose levels. Two patients developed dose-limiting toxicities at dose level 3. One patient experienced grade 3 hypotension. A second patient experienced grade 3 vomiting, grade 4 diarrhea, and severe hand-foot syndrome. Two partial responses and one complete response have been observed. Early trends suggest that this regimen is active in metastatic breast cancer and is well tolerated. Completion of this study is anticipated in 1999.
AB - This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer. This trial was initiated to 1) determine the maximum tolerated dose and dose-limiting toxicities of UFT plus calcium folinate (Orzel) administered three times per day for 21 days in combination with paclitaxel; and 2) define the appropriate dose for phase H testing. Thus far, 14 patients have been accrued to three dose levels. Two patients developed dose-limiting toxicities at dose level 3. One patient experienced grade 3 hypotension. A second patient experienced grade 3 vomiting, grade 4 diarrhea, and severe hand-foot syndrome. Two partial responses and one complete response have been observed. Early trends suggest that this regimen is active in metastatic breast cancer and is well tolerated. Completion of this study is anticipated in 1999.
UR - http://www.scopus.com/inward/record.url?scp=0032775864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032775864&partnerID=8YFLogxK
M3 - Article
VL - 13
SP - 69
EP - 70
JO - Oncology
JF - Oncology
SN - 0890-9091
IS - 7 SUPPL.
ER -